APT trades at $1.27 in oversold territory with RSI at 30.78. Technical analysis suggests potential bounce to $1.41 resistance within the next week, though bearishAPT trades at $1.27 in oversold territory with RSI at 30.78. Technical analysis suggests potential bounce to $1.41 resistance within the next week, though bearish

APT Price Prediction: Aptos Eyes $1.41 Recovery Despite Oversold Conditions

4 min read

APT Price Prediction: Aptos Eyes $1.41 Recovery Despite Oversold Conditions

Caroline Bishop Feb 03, 2026 11:16

APT trades at $1.27 in oversold territory with RSI at 30.78. Technical analysis suggests potential bounce to $1.41 resistance within the next week, though bearish momentum persists below key moving...

APT Price Prediction: Aptos Eyes $1.41 Recovery Despite Oversold Conditions

APT Price Prediction Summary

• Short-term target (1 week): $1.32-$1.41 • Medium-term forecast (1 month): $1.22-$1.47 range
• Bullish breakout level: $1.54 (SMA 20) • Critical support: $1.22

What Crypto Analysts Are Saying About Aptos

Recent analyst coverage has provided mixed but cautiously optimistic Aptos forecasts. Luisa Crawford noted on February 1st that "Aptos (APT) trades at $1.24 in oversold territory with RSI at 27.60. Technical analysis suggests potential bounce to $1.41 resistance, but bearish momentum persists below key moving averages." This target of $1.41 aligns with current resistance levels identified in our technical analysis.

MEXC projected APT reaching $1.383 by January 31st, while Cryptopredictions.com established a broader range with a minimum price of $1.230 and maximum of $1.808 for January 2026, with an average price target of $1.447.

While specific analyst predictions remain limited, on-chain metrics from major data platforms suggest Aptos is trading in a consolidation phase with potential for near-term recovery based on oversold conditions.

APT Technical Analysis Breakdown

The current APT price prediction relies heavily on technical indicators showing oversold conditions. At $1.27, Aptos is trading significantly below all major moving averages, with the SMA 20 at $1.54 representing a 21% premium to current levels.

The RSI reading of 30.78 indicates neutral territory but close to oversold conditions, suggesting potential for a technical bounce. The MACD histogram at 0.0000 shows bearish momentum has stalled, though it hasn't yet turned bullish.

Bollinger Bands analysis reveals APT is positioned at 0.11, meaning it's trading very close to the lower band at $1.19, which often signals oversold conditions and potential reversal. The upper band sits at $1.89, indicating significant upside potential if bullish momentum returns.

Key support levels are established at $1.24 (immediate) and $1.22 (strong support), while resistance appears at $1.29 (immediate) and $1.32 (strong resistance).

Aptos Price Targets: Bull vs Bear Case

Bullish Scenario

In an optimistic APT price prediction scenario, a break above the immediate resistance at $1.29 could trigger momentum toward $1.32 and potentially Crawford's target of $1.41. This represents a 11% upside from current levels.

A sustained move above the SMA 20 at $1.54 would signal a more significant trend reversal, potentially opening the door to test the SMA 50 at $1.66. Technical confirmation would require increasing volume and RSI breaking above 50.

The ultimate bullish target based on Bollinger Band analysis suggests a move toward the upper band at $1.89, though this would require significant fundamental catalysts.

Bearish Scenario

The bearish case for this Aptos forecast centers on a break below the strong support at $1.22. Such a move could trigger further selling toward the Bollinger Band lower support at $1.19.

A breakdown below $1.19 would invalidate the current consolidation pattern and could lead to a test of psychological support at $1.00. The distance from the SMA 200 at $3.24 illustrates the significant downtrend Aptos remains trapped within.

Risk factors include broader cryptocurrency market weakness and potential selling pressure from long-term holders looking to exit positions.

Should You Buy APT? Entry Strategy

Based on current technical conditions, a strategic entry approach for APT involves waiting for confirmation of the oversold bounce. The optimal entry zone appears to be between $1.24-$1.27, with a stop-loss placed below $1.22 to limit downside risk.

For conservative investors, waiting for a break above $1.32 with volume confirmation would provide better risk-adjusted entry, though at the cost of missing the initial bounce potential.

The daily ATR of $0.11 suggests position sizing should account for significant daily volatility, with risk management being crucial given the 24-hour trading range of $1.25-$1.30.

Conclusion

This APT price prediction suggests a near-term bounce to $1.32-$1.41 is likely based on oversold technical conditions and recent analyst targets. However, the broader trend remains bearish with Aptos trading well below major moving averages.

The probability of reaching Crawford's $1.41 target within the next week is estimated at 60%, contingent on broader market stability and volume confirmation of any upward moves.

Disclaimer: Cryptocurrency price predictions are highly speculative and subject to extreme volatility. This analysis is for informational purposes only and should not be considered financial advice. Always conduct your own research and consider your risk tolerance before making investment decisions.

Image source: Shutterstock
  • apt price analysis
  • apt price prediction
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Bitcoin ETFs Outpace Ethereum With $2.9B Weekly Surge

Bitcoin ETFs Outpace Ethereum With $2.9B Weekly Surge

The surge follows a difficult August, when investors pulled out more than $750 million while rotating capital into Ethereum-focused funds. […] The post Bitcoin ETFs Outpace Ethereum With $2.9B Weekly Surge appeared first on Coindoo.
Share
Coindoo2025/09/18 01:15
CME Group to launch options on XRP and SOL futures

CME Group to launch options on XRP and SOL futures

The post CME Group to launch options on XRP and SOL futures appeared on BitcoinEthereumNews.com. CME Group will offer options based on the derivative markets on Solana (SOL) and XRP. The new markets will open on October 13, after regulatory approval.  CME Group will expand its crypto products with options on the futures markets of Solana (SOL) and XRP. The futures market will start on October 13, after regulatory review and approval.  The options will allow the trading of MicroSol, XRP, and MicroXRP futures, with expiry dates available every business day, monthly, and quarterly. The new products will be added to the existing BTC and ETH options markets. ‘The launch of these options contracts builds on the significant growth and increasing liquidity we have seen across our suite of Solana and XRP futures,’ said Giovanni Vicioso, CME Group Global Head of Cryptocurrency Products. The options contracts will have two main sizes, tracking the futures contracts. The new market will be suitable for sophisticated institutional traders, as well as active individual traders. The addition of options markets singles out XRP and SOL as liquid enough to offer the potential to bet on a market direction.  The options on futures arrive a few months after the launch of SOL futures. Both SOL and XRP had peak volumes in August, though XRP activity has slowed down in September. XRP and SOL options to tap both institutions and active traders Crypto options are one of the indicators of market attitudes, with XRP and SOL receiving a new way to gauge sentiment. The contracts will be supported by the Cumberland team.  ‘As one of the biggest liquidity providers in the ecosystem, the Cumberland team is excited to support CME Group’s continued expansion of crypto offerings,’ said Roman Makarov, Head of Cumberland Options Trading at DRW. ‘The launch of options on Solana and XRP futures is the latest example of the…
Share
BitcoinEthereumNews2025/09/18 00:56
The FDA Is Trying To Make Corporate Free Speech Situational

The FDA Is Trying To Make Corporate Free Speech Situational

The post The FDA Is Trying To Make Corporate Free Speech Situational appeared on BitcoinEthereumNews.com. BENSENVILLE, ILLINOIS – SEPTEMBER 10: Flanked by U.S. Attorney General Pam Bondi (rear), and FDA Commissioner Marty Makary (R), Secretary of Health and Human Services Robert F. Kennedy Jr. speaks to the press outside Midwest Distribution after it was raided by federal agents on September 10, 2025 in Bensenville, Illinois. According to the company, various e-liquids were seized in the raid. (Photo by Scott Olson/Getty Images) Getty Images While running for President in 2008, Barack Obama famously chanted “Yes we can.” Love or hate his political views, Obama’s politics were quite effective. He was asking voters to think big, to envision a much better future. Advertisers no doubt approved. That’s because ads routinely evoke things not as they are, but as they could be. Gyms and exercise equipment companies don’t promote their locations and equipment with flabby, lumbering people, rather their ads show fit, upright, energetic individuals. A look ahead. Restaurants do the same with ads showing happy people enjoying impressively put together plates of food. Conversely, ads meant to convince smokers to quit have not infrequently shown the worst of the worst future downsides of the habit. The nature of advertising comes to mind as FDA commissioner Marty Makary puzzlingly brags that “The Trump Administration Is Taking On Big Pharma” in the New York Times. Makary laments pharmaceutical ads that “are filled with dancing patients, glowing smiles and catch jingles that drown out the fine print.” Not explained is whether Makary would be happier if drug companies placed ads with immobile patients, frowns, and funereal music. Seriously, what does he expect? Does he want drug companies to commit billions to drug development to accompany their achievements with imagery defined by misery? Has Makary stopped to contemplate the myriad shareholders lawsuits drugmakers would face if, upon risking staggering sums meant…
Share
BitcoinEthereumNews2025/09/18 06:29